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Research has documented the drastic reduction of unintentional
poisonings of children since the introduction of child resistant (CR)
packaging. However, studies also indicate that consumers report
diﬃculty using CR packages, in part because tests which determine
the 'senior friendliness' of CR designs that are used throughout the
world disallow people with 'overt or obvious' disabilities from being
test subjects. Our review of drug package usability suggests that the
current tests of CR packaging can and should be revised to correct
this problem. We use US legislation, regulation and data to
exemplify these points, but the conclusions are applicable to all
protocols that include the exclusionary provision.

Introduction
The testing protocols for senior friendly ⁄ child
resistant (CR) packaging frequently exclude
people with 'overt or obvious disabilities' and
those who are unable to follow written direc
tions (people with visual impairments and illit
erate subjects) as eligible test subjects. These
exclusionary practices do not adequately honour
the ethical principle of justice.
A review of the evolution of protocol testing
for senior friendly ⁄ CR packaging is presented.
This is followed by a discussion of ethical prin
ciples that should undergird research involving
human subjects and problems the exclusionary
practice presents, when viewed through this
standard. Finally, we recommend changes to the
protocol that would make it more objective and
more inclusive. Although US documents are
used to exemplify the ideas proposed, the
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implication exists wherever the exclusionary
clause is present.

History
The unintentional poisoning of children as a
result of the ingestion of household products
became a noted problem shortly after the
introduction of ﬂavoured aspirin in 1943. By
1953, the ﬁrst US Poison Control Center had
been established to serve as a central source of
information and treatment. This was followed
by the establishment of a US Clearinghouse for
Poison Control Centers in 1957. The Clearing
house was started to coordinate the eﬀorts of
local centers, gather statistical data on poison
ings, and provide diagnostic and therapeutic
information.
During this same year (1957) the over-the
counter (OTC) drug industry voluntarily
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accepted the recommendations of a medical
advisory panela to reduce the strength of chil
dren's aspirin and to limit the number of tablets
per package.1 Eﬀorts to develop 'safety closures'
were also recommended by the panel at this
time.
Taking the suggestion of the medical advisory
group, in 1959, researchers from Durham, NC
(US) reiterated the need to use 'safety closures'
for aspirin in an article that appeared in the
Journal of the American Medical Association
(JAMA).2 Ten years of hearings, debates, dis
cussion and testing ensued until 1970, when the
Congress enacted the Poison Prevention Pack
aging Act of 1970 (PPPA), the ﬁrst act of its
kind.
The Act required 'special packaging' [child
resistant (CR) packaging] on select drugs and
household chemicals. The Act deﬁnes special
packaging as, 'packaging that is designed or
constructed to be signiﬁcantly diﬃcult for chil
dren under 5 years of age to open or obtain a
toxic or harmful amount of the substance con
tained therein within a reasonable time and not
diﬃcult for ''normal adults'' to use properly, but
does not mean packaging which all such children
cannot open or obtain a toxic or harmful
amount within a reasonable time.'3
Administration of the PPPA was the responsi
bility of the Food and Drug Administration
(FDA) until October, 1972, when public law 92–
573 transferred administrative responsibility to
the Consumer Product Safety Commission
(CPSC)4 (see Table 1). The CPSC remains
responsible for the regulation of the CR packag
ing of drugs and household chemicals. Addi
tionally, in the years since the creation of CR
packaging, the PPPA, and its underlying regula
tions (16 CFR 1700–1750), have served as a model
for many of the other laws, regulations and
standards employed throughout the world1 (See
Table 1 for signiﬁcant historical events associated
with CR packaging and Table S1 for a summary
of current CR protocols from around the world).
a

The complete panel name was the 'Medical Advisory Panel
on Accidental Ingestion and Misuse of Salicylate Prepara
tions by Children.'

During the ﬁrst 25 years of US regulation
(1970–1995), package designers were so focused
on protecting children from poisoning that they
frequently forgot to account for the convenience
of the person needing the medication. The eﬀect
was the exclusion of many seniors and people
with disabilities. This was largely because of the
fact that the CPSC protocol for testing CR
packages for 'senior friendliness' speciﬁed that
adults aged 18–45 served as subjects for the
adult portion of the test.
In actual usage situations, consumers older
than 45 had diﬃculties with CR packages, and
frequently circumvented child-resistant features.
Many publications from this era, document the
diﬃculties of consumers.5–17
By the early 1990s, the CPSC recognized the
need to design a new test protocol in order to
facilitate CR package designs that could be used
more eﬀectively by consumers. As a result, on
July 21, 1995 the CPSC published a ﬁnal rule
that revised the senior-friendly portion of the
test entitled, 'Requirements for the Special
Packaging of Household Substances; Final
Rule.'18 Products packaged on or after July 21,
1998 had to comply with the new adult testing
requirements (see Fig. 1).
Because the US protocol was the ﬁrst of its
kind, it has served as the basis for numerous other
protocols (see Table S1). This fact is referenced in
the commonly adopted global standard, ISO
8317:2004, 'Child-Resistant Packaging –
Requirements and Testing Procedures for
Reclosable Packages.' The ISO document indi
cates, 'A number of other countries have intro
duced standard test methods based on similar
principles [to the US protocol]. There are now
around the world various types of packaging,
which are recognized as child-resistant, based on
the test of the nature described.' (ISO 8317, 2004).

The current test protocol for ensuring
senior friendly ⁄ child resistant packaging
As a result of the 1995 revision, the current
protocol employs 100 adults between the ages of
50 and 70 who do not have 'obvious or overt
physical or mental disabilities.'18 Figure 1
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Table 1 Historical events in legislation and regulation of child resistant closures for drug packaging
Year

Event

1943
Mid-late 40s
1953

Flavoured aspirin is introduced
Awareness of accidental ingestion builds
First Poison Control Center is established
It serves as a central source of information on ingredients, toxicity, expected symptoms and recommen
dations for treatment
National Clearinghouse for Poison Control Centers established
Coordinated efforts of local poison control, gather statistics, and provide diagnostic and therapeutic
information
FDA sponsors a meeting of the Medical Advisory Panel
Discussed accidental ingestion and misuse of salicylate preparations by children
Efforts to develop safety closures are recommended.
The drug industry voluntarily complies with recommendations to reduce the strength of children's aspirin
and to limit the number of tablets in containers to 36.
Article published in JAMA recommends the use of safety closures [4]
National Poison Prevention Week established
Public Law 87–319 designated the third week of March as Poison Prevention week. (ﬁrst observation 1962)
US House of Representatives Hearings
Established a joint committee of industrial, professional, and governmental people to develop a meth
odology.
Poison Prevention Packaging Act (PPPA)
Congress deems that legislation was necessary to secure the beneﬁts of CR containers to all consumers.
Consumer Product Safety Act
Public Law 92–573 transfers the duties of the PPPA and others to the Consumer Products Safety Com
mission (effective Spring, 1973)
National Research Act
Creates the National Commission for the Protection of Human Subjects of Biomedical and Behavioural
Research, which, in turn, publishes 'The Belmont Report'
Proposed rule to change the protocol methodology
Final rule
It applies to products packaged on or after July 21, 1998. At least 90% of 'normal' adults (50–70) must be
able to open the package twice within allotted test periods. At least 80% of children unable to open during
speciﬁed test.

1957

1957
1957

1959
1961
1966

1970
1972

1974

1990
1998

depicts the distribution of gender and age of the
adult test panel and the steps involved in the
protocol.
As the protocol begins, test participants are
screened by testers for 'obvious or overt physical
or mental disabilities;' participants determined to
have such disabilities are excluded from testing.
Participants who are determined to not have
overt or obvious disabilities then test the pack
age, individually, in well-lit, distraction free
areas. The presence of other participants or
onlookers is not allowed. Each person is pro
vided 5 min to try to open and close the package
at test if it is reclosable. If the participant is
successful, he ⁄ she has to try to open and close a
second package during a 1-min-period. If the

person is able to open and close the second
package during that period, the package gets a
pass; if not, the data is counted as a failure of the
CR package for that individual.
If, in the 5-min period, the person is not able
to open or close the package, she ⁄ he is given a 2
min screening test (1 min for each screening
package). This screening determines whether or
not the participant is able to open packages that
do NOT have CR features. The screening
packages are: a plastic snap closure (see Fig. 2a)
and continuous thread (CT-see Fig. 2b) plastic
closure that have speciﬁc dimensions and
requirements for preparation. If the person
successfully opens and closes both screening
packages, the participant continues with the
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The current test protocol for ensuring senior friendly/child resistant packaging

Figure 1 Diagram of the US CPSC senior-adult test – Reprinted with permission from 'The use of a universal design methodology
for developing child resistant drug packaging'.19
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Ethical considerations with regard to the
current protocol

(a)

An ethical analysis of the current protocol is
grounded in four broadly accepted fundamental
principles of biomedical ethics:27
1.
2.
3.
4.

respect for persons,
beneﬁcence,
non-maleﬁcence, and
justice.

Respect for persons requires that the auton
omy of individuals be honoured when decisions
are made and actions are taken that aﬀect the
course of their lives; it also restricts us from
forcing our will and values on others. Beneﬁ
cence enjoins us to do good, while non-maleﬁ
cence requires the avoidance of harm. Justice
requires us to impartially consider the eﬀects of
our actions on all persons who will be inﬂuenced
by them.
The entire process of regulating CR packaging
has been driven, in large part, by the ethical
principles of beneﬁcence and non-maleﬁcence.
(b)
Figure 2 Screening Packages (2A-Snap Closure and 2B
Continuous Thread Closure).

1-min-period testing the original CR package,
otherwise the person is eliminated from testing
and replaced with another participant. See
Fig. 1 for a schematic of the current adult test,
as dictated by the protocol.
A package passes the senior adult test if the
senior adult use eﬀectiveness (SAUE) is at least
90%. The SAUE is the percentage of adults who
both opened the package in the ﬁrst 5-min test
period and opened and properly closed the
package in the 1-min test period.
Despite the fact that the protocol was changed
to test older adults (aged 50–70 as compared
with 18–45), studies that have been done since
the 1995 revision indicate that seniors continue
to have diﬃculty with CR packages.19–24 This
problem will continue, and likely grow, as the
population ages,25,26 lives with increasing levels
of chronic conditions (see Fig. 3) and engages in
polypharmacy.

• The inadvertent poisoning of children through
toxic doses of medicine is clearly maleﬁcent,
and demanded corrective action in the middle
of the 20th century.
• Protecting the vulnerable, a population
including both children and the ill, is beneﬁ
cent; children are protected through the use of
CR packaging, and the general population of
ill persons is protected from undue diﬃculty in
gaining access to medication through the
testing process.
• Some of the restrictions on the testing process
protect industry from undue burdens (beneﬁ
cence and non-maleﬁcence) that might result
from too-stringent requirements in the regu
lations. For example, the clause in the PPPA
that CR 'does not mean packaging which all
such children cannot open or obtain a toxic or
harmful amount within a reasonable time'
makes it clear that packaging does not need be
absolutely impervious to children to pass the
protocol.
• Likewise, the stipulation that test subjects
must be 'normal adults' is also intended to

© 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd Health Expectations, 12, pp.430–437

Is the test of senior friendly ⁄ CR packaging ethical?, L Bix et al. 435
(a)

(b)

Figure 3 (a) Percentage of people age 65 and over in selected countries for 2005 and projected 2025. Source: US Census
Bureau36 (b) Estimated level of disability by age. Source: Agency on Aging37 and US Census Bureau.38

protect industry from an undue burden in
designing and manufacturing packaging.
The obvious success28,29 of the legislated and
regulated design and use of CR packaging is to
be celebrated. However, we argue that the
ethical principle of justice is inadequately
honoured in the current legislation and regu
lations because the needs of vulnerable popu
lations, people with disabilities and consumers
who experience diﬃculties opening CR pack
ages, are not being met.
We acknowledge that a major step toward
serving vulnerable populations was taken with
the 1995 revision. Additionally, the law's
allowance for the use of non-CR prescription
packages upon request for prescription drugs
or in a single size for OTCs, aids accessibility.
But does the current protocol for evaluating
ease of use go far enough? Research continues
to indicate diﬃculties associated with the use
of CR packaging,19–24,30–34 and consumers who

are forced to choose non-CR systems are not
aﬀorded the CR protections that they provide.
It appears to us that the regulations continue
to be hampered by the regulatory interpretation
of the 'normal adults' clause in the legislation.
The vagueness of this stipulation and its neces
sarily subjective interpretation by test adminis
trators has unintentionally contributed to the
continuing diﬃculties reported by many seniors
in opening drug packages.

Proposal
The visual screening for overt or obvious dis
abilities should be removed from the protocol on
several grounds.
1. 'Obvious or overt physical or mental disabi
lities' is not deﬁned and requires subjective
judgment that likely varies from one tester to
another. For example, a potential participant
using a wheelchair has an obvious physical
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disability which will lead some testers to
exclude him or her, but other testers might
reasonably conclude that this disability is
irrelevant to the person's ability to open a
medicine package and include him or her.
2. The subjectivity of the visual screening
reduces the scientiﬁc rigor of the test to the
degree that the interpretation can inﬂuence
test results.
3. The protocol already includes an objective
screening test designed to determine whether
a potential participant should be excluded,
(i.e. the screening packages – see Figs 1 and
2). This makes the subjective visual screening
redundant.
4. Removing the subjective visual screening will
allow for a greater range of adults, more
nearly representative of the population, to test
CR packaging; rigorously adhering to the
results of the objective screening will protect
industry from burdensome testing; and the
rigor of the tests will be increased.

ers' for their grandchild. Undoubtedly, even
more grandparents are the benefactors of visits
from children. For all of these households, the
use of non-CR packaging has the potential to
put children at risk.
Through this article, we hope to begin a
movement to change the test protocols
throughout the world, to better serve aging
populations, people with disabilities, and the
children in their lives.

This change can be made at the regulatory
level by deﬁning 'normal adult' (the language in
the legislation) as an individual who can pass the
objective screening test. Such an interpretation is
within the spirit of the law because the legis
lation clearly concerns the ability to open
medical packages and the objective screening
test guarantees that only adults with that ability
serve a test subjects.

Additional supporting information may be
found in the online version of this article:
Table S1. Standards and regulations for
senior-friendly child-resistant packaging for
pharmaceuticals products.
Please note: Wiley-Blackwell are not respon
sible for the content or functionality of any
supporting materials supplied by the authors.
Any queries (other than missing material)
should be directed to the corresponding author
for the article.
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Conclusion
Although children, 'normal' adults, industry,
and society as a whole have beneﬁted from the
implementation of this law, a large and growing
vulnerable population of seniors and people
with disabilities, in particular those who share
living space with children, are disserved by the
status quo. US Census 2000 enumerated, for the
ﬁrst time, the number of grandparents that were
co-residents with grandchildren under the age of
18. The Census statistics indicated that 5.8 mil
lion households (or 3.6% of those reporting)
reported this living arrangement; 35 of these,
2.4 million indicated themselves to be 'caregiv
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